Cargando…

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD

BACKGROUND: Dual bronchodilation with a long-acting muscarinic antagonist (LAMA)/long-acting β(2)-agonist (LABA) fixed-dose combination (FDC) is an established treatment strategy for chronic obstructive pulmonary disease (COPD). The relative efficacy and safety of glycopyrrolate/formoterol fumarate...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqui, Mohd Kashif, Shukla, Pragya, Jenkins, Martin, Ouwens, Mario, Guranlioglu, Deniz, Darken, Patrick, Biswas, Mousumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928544/
https://www.ncbi.nlm.nih.gov/pubmed/31868101
http://dx.doi.org/10.1177/1753466619894502
_version_ 1783482502052052992
author Siddiqui, Mohd Kashif
Shukla, Pragya
Jenkins, Martin
Ouwens, Mario
Guranlioglu, Deniz
Darken, Patrick
Biswas, Mousumi
author_facet Siddiqui, Mohd Kashif
Shukla, Pragya
Jenkins, Martin
Ouwens, Mario
Guranlioglu, Deniz
Darken, Patrick
Biswas, Mousumi
author_sort Siddiqui, Mohd Kashif
collection PubMed
description BACKGROUND: Dual bronchodilation with a long-acting muscarinic antagonist (LAMA)/long-acting β(2)-agonist (LABA) fixed-dose combination (FDC) is an established treatment strategy for chronic obstructive pulmonary disease (COPD). The relative efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI 18/9.6 μg) in patients with moderate-to-very severe COPD, compared with other licensed LAMA/LABA FDCs, was investigated using an integrated Bayesian network meta-analysis (NMA). METHODS: A systematic literature review and subsequent screening process identified randomized controlled trials of ⩾10 weeks’ duration that enrolled patients aged ⩾40 years with moderate-to-very severe COPD and included at least one LAMA/LABA FDC or open LAMA + LABA treatment arm. NMAs were conducted for outcomes including change from baseline in forced expiratory volume in 1 s (FEV(1)), St George’s Respiratory Questionnaire (SGRQ), and transition dyspnea index (TDI) parameters, annualized rate of exacerbations, use of rescue medication, adverse events, and all-cause withdrawals. Meta-regression and sensitivity analyses accounted for heterogeneity across studies. RESULTS: In total, 29 studies including 34,617 patients contributed to the NMA for efficacy or safety outcomes at week 24 or exacerbations. For all LAMA/LABA FDCs with data available, significantly greater improvements in FEV(1) [trough, peak, and area under the curve (AUC)(0–4)], SGRQ total score and TDI focal score at week 24, and annualized rate of moderate-to-severe exacerbations, were observed versus placebo. Where indirect comparisons were possible, differences between GFF MDI and other LAMA/LABA FDCs were small relative to established margins of clinical relevance, and not statistically significant. The safety and tolerability profile of GFF MDI was consistent with other LAMA/LABA FDCs and placebo. The results of the meta-regression were generally similar to the base case. CONCLUSIONS: GFF MDI demonstrated comparable efficacy and safety outcomes to other LAMA/LABA FDCs. Personalization of treatment choice within the class on the basis of other factors such as patient preference may be appropriate.
format Online
Article
Text
id pubmed-6928544
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-69285442020-01-03 Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD Siddiqui, Mohd Kashif Shukla, Pragya Jenkins, Martin Ouwens, Mario Guranlioglu, Deniz Darken, Patrick Biswas, Mousumi Ther Adv Respir Dis Meta-Analysis BACKGROUND: Dual bronchodilation with a long-acting muscarinic antagonist (LAMA)/long-acting β(2)-agonist (LABA) fixed-dose combination (FDC) is an established treatment strategy for chronic obstructive pulmonary disease (COPD). The relative efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI 18/9.6 μg) in patients with moderate-to-very severe COPD, compared with other licensed LAMA/LABA FDCs, was investigated using an integrated Bayesian network meta-analysis (NMA). METHODS: A systematic literature review and subsequent screening process identified randomized controlled trials of ⩾10 weeks’ duration that enrolled patients aged ⩾40 years with moderate-to-very severe COPD and included at least one LAMA/LABA FDC or open LAMA + LABA treatment arm. NMAs were conducted for outcomes including change from baseline in forced expiratory volume in 1 s (FEV(1)), St George’s Respiratory Questionnaire (SGRQ), and transition dyspnea index (TDI) parameters, annualized rate of exacerbations, use of rescue medication, adverse events, and all-cause withdrawals. Meta-regression and sensitivity analyses accounted for heterogeneity across studies. RESULTS: In total, 29 studies including 34,617 patients contributed to the NMA for efficacy or safety outcomes at week 24 or exacerbations. For all LAMA/LABA FDCs with data available, significantly greater improvements in FEV(1) [trough, peak, and area under the curve (AUC)(0–4)], SGRQ total score and TDI focal score at week 24, and annualized rate of moderate-to-severe exacerbations, were observed versus placebo. Where indirect comparisons were possible, differences between GFF MDI and other LAMA/LABA FDCs were small relative to established margins of clinical relevance, and not statistically significant. The safety and tolerability profile of GFF MDI was consistent with other LAMA/LABA FDCs and placebo. The results of the meta-regression were generally similar to the base case. CONCLUSIONS: GFF MDI demonstrated comparable efficacy and safety outcomes to other LAMA/LABA FDCs. Personalization of treatment choice within the class on the basis of other factors such as patient preference may be appropriate. SAGE Publications 2019-12-23 /pmc/articles/PMC6928544/ /pubmed/31868101 http://dx.doi.org/10.1177/1753466619894502 Text en © The Author(s), 2019 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Meta-Analysis
Siddiqui, Mohd Kashif
Shukla, Pragya
Jenkins, Martin
Ouwens, Mario
Guranlioglu, Deniz
Darken, Patrick
Biswas, Mousumi
Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
title Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
title_full Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
title_fullStr Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
title_full_unstemmed Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
title_short Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
title_sort systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in copd
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928544/
https://www.ncbi.nlm.nih.gov/pubmed/31868101
http://dx.doi.org/10.1177/1753466619894502
work_keys_str_mv AT siddiquimohdkashif systematicreviewandnetworkmetaanalysisoftheefficacyandsafetyofglycopyrrolateformoterolfumaratemetereddoseinhalerincomparisonwithotherlongactingmuscarinicantagonistlongactingb2agonistfixeddosecombinationsincopd
AT shuklapragya systematicreviewandnetworkmetaanalysisoftheefficacyandsafetyofglycopyrrolateformoterolfumaratemetereddoseinhalerincomparisonwithotherlongactingmuscarinicantagonistlongactingb2agonistfixeddosecombinationsincopd
AT jenkinsmartin systematicreviewandnetworkmetaanalysisoftheefficacyandsafetyofglycopyrrolateformoterolfumaratemetereddoseinhalerincomparisonwithotherlongactingmuscarinicantagonistlongactingb2agonistfixeddosecombinationsincopd
AT ouwensmario systematicreviewandnetworkmetaanalysisoftheefficacyandsafetyofglycopyrrolateformoterolfumaratemetereddoseinhalerincomparisonwithotherlongactingmuscarinicantagonistlongactingb2agonistfixeddosecombinationsincopd
AT guranliogludeniz systematicreviewandnetworkmetaanalysisoftheefficacyandsafetyofglycopyrrolateformoterolfumaratemetereddoseinhalerincomparisonwithotherlongactingmuscarinicantagonistlongactingb2agonistfixeddosecombinationsincopd
AT darkenpatrick systematicreviewandnetworkmetaanalysisoftheefficacyandsafetyofglycopyrrolateformoterolfumaratemetereddoseinhalerincomparisonwithotherlongactingmuscarinicantagonistlongactingb2agonistfixeddosecombinationsincopd
AT biswasmousumi systematicreviewandnetworkmetaanalysisoftheefficacyandsafetyofglycopyrrolateformoterolfumaratemetereddoseinhalerincomparisonwithotherlongactingmuscarinicantagonistlongactingb2agonistfixeddosecombinationsincopd